Transdermal immunization: Biological framework and translational perspectives

Expert Opinion on Drug Delivery

Volumn 10, Issue 2, 2013, Pages 183-200

  Mishra, Dinesh Kumar ^a   Dhote, Vinod ^b   Mishra, Pradyumna Kumar ^c  

^a GURU GHASIDAS UNIVERSITY   (India)

^b Truba Institute of Pharmacy   (India)

^c TATA MEMORIAL HOSPITAL   (India)

Author keywords

Immunotherapy; Nanomedicine; Translational research; Vaccine

Indexed keywords

ANTHRAX VACCINE; DIPHTHERIA TETANUS VACCINE; HEPATITIS B VACCINE; INFLUENZA VACCINE; LIPOSOME; NANOPARTICLE; VACCINE;

ANTHRAX; CELL MATURATION; DENDRITIC CELL; DIPHTHERIA; DRUG DELIVERY DEVICE; DRUG DELIVERY SYSTEM; ELECTROPORATION; GENE GUN IMMUNIZATION; HEPATITIS B; HUMAN; IMMUNE RESPONSE; INFLUENZA; IONTOPHORESIS; JET INJECTION; MICRONEEDLE; MICROTECHNOLOGY; NANOENGINEERING; NONHUMAN; REVIEW; T LYMPHOCYTE ACTIVATION; TETANUS; TRANSDERMAL DRUG ADMINISTRATION;

ADMINISTRATION, CUTANEOUS; ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNIZATION; TRANSDERMAL PATCH; TRANSLATIONAL MEDICAL RESEARCH; VACCINATION; VACCINES;

EID: 84872715829     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2013.746660     Document Type: Review

References (100)

1. Hilleman MR. Vaccines in historic evolution and perspective: a narrative of vaccine discoveries. Vaccine 2000;18:1436-47 (Pubitemid 30017824)
2. Jacobson MR, Swan A, Adegbenro A, et al. Making vaccines more acceptable-methods to prevent and minimize pain and other common adverse events associated with vaccines. Vaccine 2001;19:2418-27 (Pubitemid 32234252)
3. Levine MM. Ideal vaccines for resource poor settings. Vaccine 2011;29S:D116-25
4. Correia-Pinto JF, Csaba N, Alonso MJ. Vaccine delivery carriers: insights and future perspectives. Int J Pharm 2012; [Epub ahead of print]
5. Melgaard B. Immunization in the 21st century-the way forward. Acta Trop 2001;80:119-24 (Pubitemid 32964769)
6. Jodar L, Duclos P, Milstien JB, et al. Ensuring vaccine safety in immunization programmes-a WHO perspective. Vaccine 2001;19:1594-05 (Pubitemid 32175718)
7. O'Hagan DT, Rappuoli R. Novel approaches to pediatric vaccine delivery. Adv Drug Deliv Rev 2006;58:29-51
8. Glenn GM, Rao M, Matyas GR, et al. Skin immunization made possible by cholera toxin. Nature 1998;391:851 (Pubitemid 28157653)
9. Giudice EL, Campbell JD. Needle free vaccine delivery. Adv Drug Deliv Rev 2006;58:68-89
10. Williams AC, Barry BW. Penetration enhancers. Adv Drug Deliv Rev 2004;56:603-18 (Pubitemid 38326936)
11. Bal SM, Ding Z, van Riet E, et al. Advances in transcutaneous vaccine delivery: do all ways lead to Rome? J Control Release 2010;148:266-82
12. Li N, Peng LH, Chen X, et al. Transcutaneous vaccines: novel advances in technology and delivery for overcoming the barriers. Vaccine 2011;29:6179-90
13. Bos JD, Kapsenberg ML. The skin immune system: progress in cutaneous biology. Immunol Today 1993;14(2):75-8 (Pubitemid 23046167)
14. Bhargava A, Mishra D, Banerjee S, et al. Dendritic cell engineering for tumor immunotherapy: from biology to clinical translation. Immunotherapy 2012;4(7):703-18
15. Nestle FO, Di Meglio P, Qin JZ, et al. Skin immune sentinels in health and disease. Nat Rev Immunol 2009;9(10):679-91
16. Igyarto BZ, Haley K, Ortner D, et al. Skin-resident murine dendritic cell subsets promote distinct and opposing antigen-specific T helper cell responses. Immunity 2011;35(2):260-72
17. Dupasquier M, Prens EP, Leenen PJM. Dermal mononuclear phagocytes. In: Saeland S, editor. Recent advances in skin immunology. Research Signpost; Trivandrum, Kerala, India; 2008. p. 75-104
18. Romani N, Flacher V, Tripp CH, et al. Targeting skin dendritic cells to improve intradermal vaccination. Curr Top Microbiol Immunol 2012;351:113-38
19. Johnson-Huang LM, McNutt NS, Krueger JG, et al. Cytokine-producing dendritic cells in the pathogenesis of inflammatory skin diseases. J Clin Immunol 2009;29(3):247-56
20. Curry JL, Qin JZ, Bonish B, et al. Innate immune-related receptors in normal and psoriatic skin. Arch Pathol Lab Med 2003;127(2):178-86 (Pubitemid 36231763)
21. Ochoa MT, Loncaric A, Krutzik SR, et al. "Dermal dendritic cells" comprise two distinct populations: CD1+ dendritic cells and CD209+ macrophages. J Invest Dermatol 2008;128(9):2225-31
22. Rozis G, Benlahrech A, Duraisingham S, et al. Human langerhans' cells and dermal-type dendritic cells generated from CD34 stem cells express different toll-like receptors and secrete different cytokines in response to toll-like receptor ligands. Immunology 2008;124(3):329-38 (Pubitemid 351793465)
23. Dubsky P, Ueno H, Piqueras B, et al. Human dendritic cell subsets for vaccination. J Clin Immunol 2005;25(6):551-72 (Pubitemid 43011747)
24. Banchereau J, Briere F, Caux C, et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000;18:767-811 (Pubitemid 30365397)
25. Le Borgne M, Dubois B, Kaiserlian D. Dendritic cells of mucosa and skin: "recruited for vaccination". Med Sci 2007;23(10):819-25 (Pubitemid 350003963)
26. Steinman RM, Idoyaga J. Features of the dendritic cell lineage. Immunol Rev 2010;234(1):5-17
27. Moser M, Murphy KM. Dendritic cell regulation of TH1-TH2 development. Nat Immunol 2000;1:199-05
28. Biedermann T, Rocken M, Carballido JM. TH1 and TH2 lymphocyte development and regulation of TH cell-mediated immune responses of the skin. J Invest Dermatol Symp Proc 2004;9(1):5-14 (Pubitemid 38096191)
29. Sokolovska A, Hem SL, HogenEsch H. Activation of dendritic cells and induction of CD4+ T cell differentiation by aluminum-containing adjuvants. Vaccine 2007;25:4575-85 (Pubitemid 46734537)
30. Zhou W, Peng Q, Li K, et al. Role of dendritic cell synthesis of complement in the allospecific T cell response. Mol Immunol 2007;44:57-63 (Pubitemid 44647110)
31. Tacken PJ, Torensma R, Figdor CG. Targeting antigens to dendritic cells in vivo. Immunobiology 2006;211:599-08
32. Glenn GM, Scharton-Kersten T, Alving CR. Advances in vaccine delivery: transcutaneous immunization. Expert Opin Invest Drugs 1999;8(6):797-05 (Pubitemid 29253494)
33. Scharton-Kersten T, Glenn GM, Vassell R, et al. Principles of transcutaneous immunization using cholera toxin as an adjuvant. Vaccine 1999;17:S37-43 (Pubitemid 29457534)
34. Peachman KK, Mclean DM, Tong JC, et al. Ganglioside GM1 binding peptides: a potential adjuvant for transcutaneous immunization. Open Immunol J 2009;2:94-102
35. Warger T, Schild H, Rechtsteiner G. Initiation of adaptive immune responses by transcutaneous immunization. Immunol Lett 2007;109:13-20 (Pubitemid 46365972)
36. Hammond SA, Tsonis C, Sellins K, et al. Transcutaneous immunization of domestic animals: opportunities and challenges. Adv Drug Deliv Rev 2000;43:45-55
37. Glenn GM, Scharton-Kersten T, Vassell R, et al. Transcutaneous immunization using bacaterial ADP-ribosylating exotoxins as antigens and adjuvants. Infect Immun 1999;67:1100-6 (Pubitemid 29108483)
38. Foged C, Arigita C, Sundblad A, et al. Interaction of dendritic cells with antigen-containing liposomes: effect of bilayer composition. Vaccine 2004;22:1903-13 (Pubitemid 38581059)
39. Paul A, Cevc G, Bachhawat BK. Transdermal immunization with large proteins by means of ultradeformable drug carriers. Vaccine 1998;16(2/3):188-95
40. Babiuk S, Baca-Estrada M, Babiuk LA, et al. Cutaneous vaccination: the skin as an immunologically active tissue and the challenge of antigen delivery. J Control Release 2000;66:199-214 (Pubitemid 30160857)
41. Glenn GM, Taylor DN, Li XR, et al. Transcutaneous immunization: a human vaccine delivery strategy using a patch. Nat Med 2000;6:1403-6 (Pubitemid 32001027)
42. Gaspari AA, Jenkins MR, Katz SI. Induction of in vivo hyporesponsiveness to contact allergens by hapten-modified Ia+ keratinocytes. J Immunol 1991;147:4155-61
43. Bos JD. editor. Skin immune system. CRC Press, USA; 1990. p. 57-87; 257-91
44. Shahiwala A, Vyas TK, Amiji MM. Nanocarriers for systemic and mucosal vaccine delivery. Recent Pat Drug Deliv Formul 2007;1:1-9
45. Karande P, Arora A, Pham TK, et al. Transcutaneous immunization using common chemicals. J Control Release 2009;138:134-40
46. Peachman KK, Rao M, Alving CR. Immunization with DNA through the skin. Methods 2003;31:232-42 (Pubitemid 37162796)
47. Mumper RJ, Cui Z. Genetic immunization by jet injection of targeted pDNA-coated nanoparticles. Methods 2003;31:255-62 (Pubitemid 37162798)
48. Rao SS, Gomez P, Mascola JR, et al. Comparative evaluation of three different intramuscular delivery methods for DNA immunization in a nonhuman primate animal model. Vaccine 2006;24:367-73 (Pubitemid 41790440)
49. Banga AK, Prausnitz MR. Assessing the potential of skin electroporation for the delivery of protein and gene based drugs. Trends Biotechnol 1998;16(10):408-12 (Pubitemid 29037479)
50. Medi BM, Hoselton S, Marepalli RB, et al. Skin targeted DNA vaccine delivery using electroporation in rabbits I: efficacy. Int J Pharm 2005;294:53-63 (Pubitemid 40462322)
51. Zhao YL, Murthy SN, Manjili MH, et al. Induction of cytotoxic T-lymphocytes by electroporation enhanced needle-free skin immunization. Vaccine 2006;24:1282-90 (Pubitemid 43222035)
52. Schuetz YB, Schuetza B, Carrupt P, et al. Structure-permeation relationships for the non-invasive transdermal delivery of cationic peptides by iontophoresis. Eur J Pharm Sci 2006;29:53-9 (Pubitemid 44294860)
53. Oldenburg KR, Vo KT, Smith GA, et al. Iontophoretic delivery of oligonucleotides across full thickness hairless mouse skin. J Pharm Sci 1995;84:915-21
54. Mitragotri S, Edwards DA, Blankschtein D, et al. A mechanistic study of ultrasonically enhanced transdermal drug delivery. J Pharm Sci 1995;84:697-06
55. Tezel A, Paliwal S, Shen Z, et al. Low-frequency ultrasound as a transcutaneous immunization adjuvant. Vaccine 2005;23:3800-7 (Pubitemid 40704743)
56. Ogura M, Paliwal S, Mitragotri S. Low frequency sonophoresis: current status and future prospects. Adv Drug Deliv Rev 2008;60:1218-23
57. Lee S, McAuliffe DJ, Flotte TJ, et al. Photomechanical transcutaneous delivery of macromolecules. J Invest Dermatol 1998;111:925-9 (Pubitemid 29115155)
58. Cross SE, Roberts MS. Physical enhancement of transdermal drug application: is delivery technology keeping up with pharmaceutical development? Curr Drug Deliv 2004;1(1):81-92
59. Park J, Allen MG, Prausnitz MR. Biodegradable polymer microneedles: fabrication, mechanics and transdermal drug delivery. J Control Release 2005;104:51-66 (Pubitemid 40615235)
60. van der Maaden K, Jiskoot W, Bouwstra J. Microneedle technologies for transdermal drug and vaccine delivery. J Control Release 2012;161:645-55
61. Andrianov AK, Mutwiri G. Intradermal immunization using coated microneedles containing an immunoadjuvant. Vaccine 2012;30:4355-60
62. Chen D, Erickson CA, Endres RL, et al. Adjuvantation of epidermal powder immunization. Vaccine 2001;19:2908-17 (Pubitemid 32244284)
63. Dean HJ, Fuller D, Osorio JE. Powder and particle-mediated approaches for delivery of DNA and protein vaccines into the epidermis. Comp Immunol Microbiol Infect Dis 2003;26:373-88 (Pubitemid 37168474)
64. Wischke C, Borchert H, Zimmermann J, et al. Stable cationic microparticles for enhanced model antigen delivery to dendritic cells. J Control Release 2006;114:359-68 (Pubitemid 44310820)
65. Christine-Lutsiak ME, Robinson DR, Coester C, et al. Analysis of poly (d, llactic-co-glycolic acid) nanosphere uptake by human dendritic cells and macrophages in vitro. Pharm Res 2002;19(10):1480-7 (Pubitemid 35266552)
66. Saraf S, Mishra D, Asthana A, et al. Lipid microparticles for mucosal immunization against hepatitis B. Vaccine 2006;24:45-56 (Pubitemid 41722204)
67. Mishra H, Mishra D, Mishra PK, et al. Evaluation of solid lipid nanoparticles as carriers for delivery of hepatitis B surface antigen for vaccination using subcutaneous route. J Pharm Pharm Sci 2010;13(4):495-09
68. Kohli AK, Alpar HO. Potential use of nanoparticles for transcutaneous vaccine delivery: effect of particle size and charge. Int J Pharm 2004;275:13-17 (Pubitemid 38481516)
69. Zasadzinski JA, Wong B, Forbes N, et al. Novel methods of enhanced retention in and rapid, targeted release from liposomes. Curr Opin Colloid Interface Sci 2011;16:203-14
70. Shahiwala A, Vyas TK, Amiji MM. Nanocarriers for systemic and mucosal vaccine delivery. Recent Pat Drug Deliv Formul 2007;1:1-9
71. Dubey V, Mishra D, Asthana A, et al. Transdermal delivery of a pineal hormone melatonin via elastic liposomes. Biomaterials 2006;27:3491-6
72. Mishra D, Garg M, Dubey V, et al. Elastic liposomes mediated transdermal delivery of an anti-hypertensive agent: propranolol hydrochloride. J Pharm Sci 2007;96:145-55 (Pubitemid 46087346)
73. Cevc G, Blume G. Lipid vesicles penetrate into intact skin owing to the transdermal osmotic gradients and hydration force. Biochim Biophys Acta 1992;1104:226-32
74. Cevc G. Lipid suspensions on the skin. Penetration enhancement, vesicle penetration and transdermal drug delivery. Crit Rev Ther Drug Carrier Syst 1996;13:257-88
75. Mishra D, Dubey V, Asthana A, et al. Elastic liposomes mediated transcutaneous immunization against Hepatitis B. Vaccine 2006;24:4847-55 (Pubitemid 43776800)
76. Mishra D, Mishra PK, Dubey V, et al. Evaluation of uptake and generation of immune response by murine dendritic cells pulsed with Hepatitis B surface antigen loaded elastic liposomes. Vaccine 2007;25(39-40):6939-44 (Pubitemid 47391101)
77. Elsayed MMA, Abdallah OY, Naggar VF, et al. Lipid vesicles for skin delivery of drugs: reviewing three decades of research. Int J Pharm 2007;332:1-16 (Pubitemid 46237706)
78. Dubey V, Mishra D, Nahar M, et al. Vesicles as tools for the modulation of skin permeability. Expert Opin Drug Deliv 2007;4(6):579-93 (Pubitemid 350193397)
79. Touitou E, Alkabes M, Dayan N. Ethosomes: novel lipid vesicular system for enhanced delivery. Pharm Res 1997;S14:305-6
80. Touitou E, Dayan N, Bergelson L, et al. Ethosomes-novel vesicular carriers for enhanced delivery: characterization and skin penetration properties. J Control Release 2000;65:403-18 (Pubitemid 30122942)
81. Fynan EF, Webster RG, Fuller DH, et al. DNA vaccines: protective immunizations by parenteral, mucosal, and gene gun inoculations. Proc Natl Acad Sci USA 1993;90(24):11478-82 (Pubitemid 24008662)
82. Zarozinski CC, Fynan EF, Selin LK, et al. Protective CTL-dependent immunity and enhanced immunopathology in mice immunized by particle bombardment with DNA encoding an internal virion protein. J Immunol 1995;154:4010-17
83. Regnier V, Preat V. Localization of a FITC-labeled phosphorothioate oligodeoxynucleotide in the skin after topical delivery by iontophoresis and electroporation. Pharm Res 1998;15(10):1596-02 (Pubitemid 28465747)
84. Mishra A, Ganga S, Upadhyay P. Needle-free, non-adjuvanted skin immunization by electroporation-enhanced transdermal delivery of diphtheria toxoid and a candidate peptide vaccine against hepatitis B virus. Vaccine 1999;18(5-6):517-23 (Pubitemid 29462609)
85. Shi Z, Zeng M, Yang G, et al. Protection against tetanus by needle-free inoculation of adenovirus-vectored nasal and epicutaneous vaccines. J Virol 2001;75(23):11474-82 (Pubitemid 33063239)
86. Heckert RA, Elankumaran S. Topical DNA immunization with DMSO. Vet Immunol Immunopathol 2002;89:67-81
87. Bramson J, Dayball K, Evelegh C, et al. Enabling topical immunization via microporation: a novel method for pain-free and needle-free delivery of adenovirus-based vaccines. Gene Ther 2003;10(3):251-60 (Pubitemid 36204414)
88. Matyas GR, Friedlander AM, Glenn GM, et al. Needle-free skin patch vaccination method for anthrax. Infect Immun 2004;72(2):1181-3 (Pubitemid 38166706)
89. Upadhyay P. Enhanced transdermal-immunization with diptheria-toxoid using local hyperthermia. Vaccine 2006;24:5593-8 (Pubitemid 43867101)
90. Glenn GM, Flyer DC, Ellingsworth LR, et al. Transcutaneous immunization with heat-labile enterotoxin: development of a needle-free vaccine patch. Expert Rev Vaccines 2007;6(5):809-19 (Pubitemid 47607855)
91. Vogt A, Mahe B, Costagliola D, et al. Transcutaneous anti-influenza vaccination promotes both CD4 and CD8 T cell immune responses in humans. J Immunol 2008;180(3):1482-9
92. Mishra D, Mishra PK, Dubey V, et al. Systemic and mucosal immune response induced by transcutaneous immunization using Hepatitis B surface antigen-loaded modified liposomes. Eur J Pharm Sci 2008;33:424-33
93. Kim YC, Yuan FS, Yoo DG, et al. Improved influenza vaccination in the skin using vaccine coated microneedles. Vaccine 2009;27:6932-8
94. Combadiere B, Vogt A, Mahe B, et al. Preferential amplification of CD8 effector-T cells after transcutaneous application of an inactivated influenza vaccine: a randomized phase I trial. PLoS One 2010;5(5):e10818
95. Kim YC, Quan FS, Yoo DG, et al. Enhanced memory responses to seasonal H1N1 influenza vaccination of the skin with the use of vaccine-coated microneedles. J Infect Dis 2010;201(2):190-8
96. Matsuo K, Ishii Y, Quan YS, et al. Transcutaneous vaccination using a hydrogel patch induces effective immune responses to tetanus and diphtheria toxoid in hairless rat. J Control Release 2011;149(1):15-20
97. Ding Z, Bal SM, Romeijn S, et al. Transcutaneous immunization studies in mice using diphtheria toxoid-loaded vesicle formulations and a microneedle array. Pharm Res 2011;28(1):145-58
98. Bal SM, Slutter B, Jiskoot W, et al. Small is beautiful: N-trimethyl chitosan-ovalbumin conjugates for microneedle-based transcutaneous immunization. Vaccine 2011;29:4025-32
99. Hirobe S, Matsuo K, Quan YS, et al. Clinical study of transcutaneous vaccination using a hydrogel patch for tetanus and diphtheria. Vaccine 2012;30:1847-54
100. Anto V, Marie GM, John BC, et al. Coated microneedle arrays for transcutaneous delivery of live virus vaccines. J Control Release 2012;159:34-42